1. In the randomized controlled trial, dolutegravir treatment was noninferior to a regimen containing a ritonavir-boosted protease inhibitor (PI) for treating human immunodeficiency virus (HIV). 2. Dolutegravir treatment for HIV was not associated with an increased risk of adverse events as compared to ritonavir-boosted treatment. Evidence Rating Level: 1 (Excellent) Study Rundown: Currently, the World Health Organization
1. In the randomized controlled trial, dolutegravir treatment was noninferior to a regimen containing a ritonavir-boosted protease inhibitor (PI) for treating human immunodeficiency virus (HIV). 2. Dolutegravir treatment for HIV was not associated with an increased risk of adverse events as compared to ritonavir-boosted treatment. Evidence Rating Level: 1 (Excellent) Study Rundown: Currently, the World